SCHEMBL22683771

SCHEMBL22683771

Cc1cccc2cc(Cc3ccc4ccccc4c3)ncc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 4/20 0.48
BACE1 P56817 1/20 0.45
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
CYP1A2 P05177 2/20 0.41
CYP2A6 P11509 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALOX5 P09917 1/20 0.39
NQO1 P15559 1/20 0.38
CYP2D6 P10635 1/20 0.38
NFKB1 P19838 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
TBXA2R P21731 1/20 0.37
PTGER4 P35408 1/20 0.37
PTGFR P43088 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18571835 0.88 PDE10A (0.42) PDE10ABACE1ALDH1A1CYP17A1
SCHEMBL21363719 0.78 CYP2A6 (0.50) PDE10ABACE1HTR2AHTR2CHTR2B
SCHEMBL23593720 0.77 CYP1A2 (0.44) PDE10ACYP1A2CYP2A6ALDH1A1HPGD
SCHEMBL21031190 0.75 PDE10A (0.52) PDE10ABACE1CYP1A2CYP2A6
SCHEMBL3119876 0.73 CYP1A2 (0.46) PDE10AHTR2CHTR2BCYP1A2CYP2A6
SCHEMBL23715914 0.72 CYP1A2 (0.48) PDE10AHTR2BCYP1A2CYP2A6ALDH1A1
SCHEMBL25381582 0.71 CYP2A6 (0.55) PDE10AHTR2AHTR2CHTR2BCYP1A2
SCHEMBL24659178 0.70 CYP1A2 (0.44) CYP1A2CYP2A6ALDH1A1HPGDHSD17B10
SCHEMBL3128182 0.70 PDE10A (0.52) PDE10AHTR2CHTR2BCYP1A2CYP2A6
SCHEMBL20827080 0.70 CYP1A2 (0.49) PDE10ACYP1A2CYP2A6ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11318157-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2022-05-03 US disclosed
US-20200360416-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11318157-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT6, PRMT1 PDE10A 2051/4885BACE1 1835/4885HTR2A 4270/4885
US-20200360416-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 PDE10A 2247/4885BACE1 2389/4885HTR2A 4289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.